Parkman Healthcare Partners LLC Decreases Stock Position in RxSight, Inc. (NASDAQ:RXST)

Parkman Healthcare Partners LLC lessened its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 37.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 184,320 shares of the company's stock after selling 112,419 shares during the period. Parkman Healthcare Partners LLC owned about 0.46% of RxSight worth $9,111,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in RXST. Amalgamated Bank grew its stake in RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after purchasing an additional 207 shares during the period. Principal Financial Group Inc. lifted its position in RxSight by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 36,046 shares of the company's stock valued at $1,782,000 after acquiring an additional 240 shares during the period. Crossmark Global Holdings Inc. boosted its stake in RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock worth $473,000 after acquiring an additional 242 shares in the last quarter. RiverPark Advisors LLC grew its holdings in RxSight by 9.6% in the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock worth $203,000 after purchasing an additional 297 shares during the period. Finally, CWM LLC increased its stake in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company's stock valued at $25,000 after purchasing an additional 371 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at RxSight

In related news, insider Ilya Goldshleger sold 3,105 shares of RxSight stock in a transaction on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the transaction, the insider now owns 42,246 shares in the company, valued at approximately $1,946,695.68. The trade was a 6.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now owns 10,902 shares in the company, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,807 shares of company stock worth $3,202,275 in the last ninety days. Insiders own 9.36% of the company's stock.

RxSight Trading Down 0.9 %

RXST stock traded down $0.40 on Wednesday, hitting $43.16. The company had a trading volume of 640,142 shares, compared to its average volume of 487,807. RxSight, Inc. has a 12-month low of $31.34 and a 12-month high of $66.54. The stock's 50-day simple moving average is $48.36 and its 200 day simple moving average is $51.94. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -52.63 and a beta of 1.11.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wells Fargo & Company cut their price target on RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Oppenheimer cut their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus cut their price objective on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price objective on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.